RPCAR-01

N/A

Report date: 2026/05/02 20:00:18

Base Information

Drug NameRPCAR-01

Drug Alias NameAutologous CAR T Cells Targeting GPC3 therapy (Roswell Park Cancer Institute)RPCAR-01RPCAR01

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionGlypican-3 modulatorsT lymphocyte replacements

TargetsGlypican-3

Therapy Area/IndicationsCarcinoma, Hepatocellular

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesRoswell Park Cancer Institute

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesRoswell Park Cancer Institute

Active IndicationsN/A

Inactive IndicationsCarcinoma, Hepatocellular

Other Information

ATC CodeN/A